Every 424B that InflaRx N.V. (IFRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow IFRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IFRX filings page.
InflaRx N.V. is registering and may offer and sell, from time to time, ordinary shares with an aggregate offering price of up to $65,000,000 through Leerink Partners LLC in an at-the-market offering under an existing Form F-3 shelf. Sales may be made on Nasdaq or other permitted methods, with Leerink receiving up to 3.0% of gross proceeds as commission. Assuming sales at $2.01 per share, up to 32,338,308 ordinary shares would be outstanding after the offering, compared with 147,368,221 shares outstanding as of June 30, 2026. As of that date, net tangible book value was $165.6 million, or $1.12 per share; on a pro forma basis after a full $65 million sale it would be $228.5 million, or $1.27 per share, implying purchaser dilution of $0.74 per share at the assumed price. InflaRx reports under IFRS, focuses on anti-C5a/C5aR inflammatory therapies, and plans to use any net proceeds primarily for research and development of its clinical and preclinical programs, as well as working capital and general corporate purposes.
InflaRx N.V. is offering 75,000,000 ordinary shares at $2.00 per share in a registered primary offering, implying aggregate gross proceeds of $150,000,000. Delivery is expected on May 7, 2026. The company estimates net proceeds of approximately $140.5 million, which it intends to use to advance its pipeline and for working capital and general corporate purposes.
The prospectus supplement discloses that shares outstanding would be 147,292,859 ordinary shares immediately after the offering, based on 72,292,859 ordinary shares outstanding as of March 31, 2026. InflaRx reported total funds available of approximately €39.7 million as of March 31, 2026 and states a projected cash runway through 2029 including the offering proceeds. The supplement highlights a strategic refocus toward development of izicopan and recent non-clinical data comparing reactive metabolite formation versus a comparator.
InflaRx N.V. files a preliminary prospectus supplement to offer ordinary shares on Nasdaq, describing terms, use of proceeds and updated corporate plans. The company highlights its lead program izicopan and reports new non‑clinical data (May 2026) suggesting lower reactive metabolite formation versus avacopan in human liver microsomes.
As of March 31, 2026, total funds available were approximately €39.7 million (cash €15.0 million; marketable securities €24.7 million), and shares outstanding were 72,292,859. Management stated a projected cash runway through 2029, including proceeds from this offering. The supplement discloses a Chief Medical Officer resignation effective August 2026, PFIC status likelihood for 2021–2025, and customary Dutch and U.S. tax discussions.